Mary K. Danks

5.9k total citations
99 papers, 5.0k citations indexed

About

Mary K. Danks is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Mary K. Danks has authored 99 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Molecular Biology, 39 papers in Oncology and 23 papers in Neurology. Recurrent topics in Mary K. Danks's work include Cancer therapeutics and mechanisms (54 papers), Neuroblastoma Research and Treatments (23 papers) and Cholinesterase and Neurodegenerative Diseases (20 papers). Mary K. Danks is often cited by papers focused on Cancer therapeutics and mechanisms (54 papers), Neuroblastoma Research and Treatments (23 papers) and Cholinesterase and Neurodegenerative Diseases (20 papers). Mary K. Danks collaborates with scholars based in United States, Canada and United Kingdom. Mary K. Danks's co-authors include William T. Beck, Philip M. Potter, Christopher L. Morton, D. Parker Suttle, Peter J. Houghton, Karen S. Aboody, Monika Wierdl, Janice L. Hyatt, Randy M. Wadkins and József Najbauer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Mary K. Danks

97 papers receiving 4.9k citations

Peers

Countries citing papers authored by Mary K. Danks

Since Specialization

Citations

This map shows the geographic impact of Mary K. Danks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary K. Danks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary K. Danks more than expected).

Fields of papers citing papers by Mary K. Danks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary K. Danks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary K. Danks. The network helps show where Mary K. Danks may publish in the future.

Co-authorship network of co-authors of Mary K. Danks

This figure shows the co-authorship network connecting the top 25 collaborators of Mary K. Danks. A scholar is included among the top collaborators of Mary K. Danks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary K. Danks. Mary K. Danks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Establishment of patient-derived 3D in vitro models of sarcomas: literature review and guidelines on behalf of the FORTRESS working group 2025 ·Neoplasia ·(unknown), (unknown), Francesca Bersani, (unknown), Sandro Pasquali, Scott E. Umbaugh, Michael T. Meister, Mary K. Danks, (unknown), (unknown), Manuela Krumbholz, Siyer Roohani, Dominique Heymann, Florencia Cidre‐Aranaz, Agnieszka Woźniak, Patrick Schöffski, Judith V.M.G. Bovée, Alessandra Merlini, (unknown)	1
2	Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma 2025 ·Molecular Oncology ·(unknown), Mary K. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana Teresa Amaral, Juan Díaz‐Martín, David S. Moura, Javier Martín‐Broto, (unknown), Donald M. Salter, (unknown), Graeme R. Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton	0
3	New therapeutic targets for the treatment of high‐risk neuroblastoma 2009 ·Journal of Cellular Biochemistry ·Lars M. Wagner, Mary K. Danks	84
4	Stem and progenitor cell-mediated tumor selective gene therapy 2008 ·Gene Therapy ·Karen S. Aboody, József Najbauer, Mary K. Danks	226
5	Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report 2007 ·Clinical Cancer Research ·Alberto Broniscer, Sridharan Gururangan, Tobey J. MacDonald, Stewart Goldman, Roger J. Packer, Clinton F. Stewart, Dana Wallace, Mary K. Danks, Henry S. Friedman, Tina Young Poussaint, Larry E. Kun, James M. Boyett, Amar Gajjar	49
6	Pilot Study to Evaluate MYCN Expression as a Neuroblastoma Cell Marker to Detect Minimal Residual Disease by RT-PCR 2006 ·Journal of Pediatric Hematology/Oncology ·Lars M. Wagner, (unknown), Sylvie M. Guichard, Susana C. Raimondi, Victor M. Santana, Wayne L. Furman, Phillip Barnette, Mary K. Danks	1
7	Development of a Tumor-Selective Approach to Treat Metastatic Cancer 2006 ·PLoS ONE ·Karen S. Aboody, (unknown), Elizabeth Garcia, Marianne Z. Metz, Joseph Najbauer, Kristine A. Justus, Doris A. Phelps, Joanna S. Remack, Karina J. Yoon, (unknown), Seung Up Kim, Carlotta A. Glackin, Philip M. Potter, Mary K. Danks	108
8	Gains of chromosome 17q common in high-risk neuroblastomas do not involve the topoisomerase IIα gene: FISH and quantitative-PCR (Q-PCR) studies of six neuroblastoma cell lines 2004 ·Cancer Research ·Kyoung Jin P. Yoon, Marcus B. Valentine, Virginia Valentine, Susan T. Ragsdale, Mary K. Danks	1
9	Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. 2003 ·PubMed ·Kyoung Jin P. Yoon, (unknown), Christopher L. Morton, William G. Bornmann, Richard Lee, Philip M. Potter, Mary K. Danks	14
10	p53-Mediated Regulation of Expression of a Rabbit Liver Carboxylesterase Confers Sensitivity to 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) 2003 ·Journal of Pharmacology and Experimental Therapeutics ·Monika Wierdl, Christopher L. Morton, Linda C. Harris, Mary K. Danks, John D. Schuetz, Philip M. Potter	1
11	Crystal Structure of Human Carboxylesterase 1 Complexed with the Alzheimer's Drug Tacrine 2003 ·Chemistry & Biology ·Sompop Bencharit, Christopher L. Morton, Janice L. Hyatt, Peter Kühn, Mary K. Danks, Philip M. Potter, Matthew R. Redinbo	144
12	Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. 2002 ·PubMed ·Lars M. Wagner, Sylvie M. Guichard, (unknown), Christopher L. Morton, (unknown), Richard A. Ashmun, Linda C. Harris, Peter J. Houghton, Philip M. Potter, Mary K. Danks	27
13	Isolation and characterization of a cDNA encoding a horse liver butyrylcholinesterase 2000 ·Biochemical Pharmacology ·Monika Wierdl, Christopher L. Morton, Mary K. Danks, Philip M. Potter	16
14	Differences in epitope accessibility of p53 monoclonal antibodies suggest at least three conformations or states of protein binding of p53 protein in human tumor cell lines 1998 ·Cell Death and Differentiation ·Mary K. Danks, (unknown), (unknown), (unknown), Linda C. Harris	21
15	Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. 1998 ·PubMed ·Sylvie M. Guichard, Christopher L. Morton, (unknown), Clinton F. Stewart, Mary K. Danks, Philip M. Potter	30
16	Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy 1995 ·Cytometry ·Sharyn D. Baker, Randy M. Wadkins, Clinton F. Stewart, William T. Beck, Mary K. Danks	35
17	Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors 1995 ·Cancer Chemotherapy and Pharmacology ·Peter J. Houghton, Pamela J. Cheshire, (unknown), (unknown), Henry S. Friedman, Mary K. Danks, Janet A. Houghton	330
18	Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide 1994 ·International Journal of Cancer ·Louise K. Hosking, Richard D. H. Whelan, Sharon A. Shellard, Sally L. Davies, Ian D. Hickson, Mary K. Danks, (unknown)	11
19	Loss of tumorigenicity in a methotrexate-resistant human leukemia cell line 1993 ·Cancer Genetics and Cytogenetics ·Anna B. Hill, Jeffrey M. Trent, Floyd H. Thompson, Mary K. Danks, William T. Beck	2
20	Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26 1988 ·Biochemistry ·Mary K. Danks, Carla Schmidt, Margaret C. Cirtain, D. Parker Suttle, William T. Beck	199

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact